ARS Pharmaceuticals (SPRY) Interest Expenses (2026)

ARS Pharmaceuticals' (SPRY) quarterly Interest Expenses came in at $2.4 million in Q1 2026.

ARS Pharmaceuticals (SPRY) Interest Expenses (2026) Analysis & Trends

ARS Pharmaceuticals has disclosed Interest Expenses across 1 years of filings, most recently posting $2.4 million for Q1 2026.

Interest Expenses for Q1 2026 came in at $2.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (changed N/A YoY), and the FY2025 annual result was $2.6 million, changed N/A from the prior year.
Interest Expenses came in at $2.4 million for Q1 2026 at ARS Pharmaceuticals.
In the past five years, Interest Expenses ranged from a high of $2.4 million in Q1 2026 to a low of $2.4 million in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int Expense (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-5.50 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-332,000.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	61,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-2,753.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-5.58 Mn
10	ARS Pharmaceuticals	954.24 Mn	753.27 Mn	-	2.44 Mn

Historic Data

Download Data

Date	Value
Mar 31, 2026	2.44 Mn
Mar 31, 2026	2.44 Mn